Loading clinical trials...
Loading clinical trials...
a Clinical Trial Phase II Prospective, Single-arm Study of Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced Non-small Cell Lung Cancer
Conditions
Interventions
Endostatin
Locations
1
China
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, Guangdong, China
Start Date
July 20, 2022
Primary Completion Date
July 20, 2023
Completion Date
December 20, 2023
Last Updated
July 7, 2022
NCT05671510
NCT03340506
NCT06066138
NCT07485114
NCT05098132
NCT04977453
Lead Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions